Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
GSK will own 68% of the combined entity, which brings together products such as Panadol and Advil
At the company’s annual meeting, being held in the City of London, chairman Dr Stephen Parker will point to the progress of SRA737, which has been licensed to Sierra Oncology
With consumer confidence at its lowest ebb for almost a year, just what is in store for M&S
Croda is acquiring Brenntag Biosector, which develops adjuvants for the human and veterinary vaccine markets
It has carried out a study involving 50 people which has shown its drug was formulated appropriately when administered in a phase III clinical trial
The publication is intended to be the first in a series of results-based reports on VAL401, an antipsychotic drug that has been re-purposed for use in oncology
Dr Jose Saro is joining the business from the Roche Innovation Center
“The annual burden of pulmonary disease in the US is estimated to be over US$150bn and Polarean expects over US$500mln in system sales just to top-tier institutes,” read Northland’s note
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.